Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

20.29 +0.72 (+3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,246,909
Open 19.89
Bid (Size) 20.20 (4)
Ask (Size) 20.44 (16)
Prev. Close 19.57
Today's Range 19.71 - 20.58
52wk Range 3.060 - 20.37
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
Via Chartmill
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
Via Benzinga

Performance

YTD
+345.93%
+345.93%
1 Month
+22.45%
+22.45%
3 Month
+77.05%
+77.05%
6 Month
+223.09%
+223.09%
1 Year
+503.87%
+503.87%

More News

Read More
ADMA Biologics Set to Join S&P SmallCap 600 Index
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
Assessing ADMA Biologics: Insights From 4 Financial Analysts
Via Benzinga
What's Going On With ADMA Biologics Stock Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
Via Benzinga
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Via Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Immunome Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
From ADMA Biologics, Inc.
Via GlobeNewswire
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
Via Investor's Business Daily
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
Via Investor's Business Daily
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.